CN114632128A - Collateral-dredging and turbid-removing formula and using method thereof - Google Patents
Collateral-dredging and turbid-removing formula and using method thereof Download PDFInfo
- Publication number
- CN114632128A CN114632128A CN202210297441.7A CN202210297441A CN114632128A CN 114632128 A CN114632128 A CN 114632128A CN 202210297441 A CN202210297441 A CN 202210297441A CN 114632128 A CN114632128 A CN 114632128A
- Authority
- CN
- China
- Prior art keywords
- eliminating
- turbidity
- dredging
- chinese medicine
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 48
- 201000005569 Gout Diseases 0.000 claims abstract description 25
- 244000189799 Asimina triloba Species 0.000 claims abstract description 13
- 235000006264 Asimina triloba Nutrition 0.000 claims abstract description 13
- 235000009467 Carica papaya Nutrition 0.000 claims abstract description 13
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 13
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 12
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 12
- 241000031023 Amana edulis Species 0.000 claims abstract description 9
- 210000000582 semen Anatomy 0.000 claims abstract description 8
- 244000281702 Dioscorea villosa Species 0.000 claims abstract description 7
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 11
- 229960001680 ibuprofen Drugs 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 241000218691 Cupressaceae Species 0.000 claims description 7
- 239000008589 Cortex Fraxini Substances 0.000 claims description 6
- 210000000941 bile Anatomy 0.000 claims description 3
- 235000012239 silicon dioxide Nutrition 0.000 claims description 3
- 241000489492 Arisaema Species 0.000 claims description 2
- 241000131329 Carabidae Species 0.000 claims description 2
- 241000258920 Chilopoda Species 0.000 claims description 2
- 240000009138 Curcuma zedoaria Species 0.000 claims description 2
- 235000003405 Curcuma zedoaria Nutrition 0.000 claims description 2
- 241001071917 Lithospermum Species 0.000 claims description 2
- 244000170916 Paeonia officinalis Species 0.000 claims description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 2
- 244000131316 Panax pseudoginseng Species 0.000 claims description 2
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 2
- 241000283966 Pholidota <mammal> Species 0.000 claims description 2
- 241000239226 Scorpiones Species 0.000 claims description 2
- 241000271897 Viperidae Species 0.000 claims description 2
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 235000019509 white turmeric Nutrition 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 5
- 241000405414 Rehmannia Species 0.000 claims 1
- 208000002193 Pain Diseases 0.000 abstract description 15
- 230000001154 acute effect Effects 0.000 abstract description 15
- 208000004880 Polyuria Diseases 0.000 abstract description 9
- 230000035619 diuresis Effects 0.000 abstract description 9
- 208000024891 symptom Diseases 0.000 abstract description 8
- 244000052769 pathogen Species 0.000 abstract description 5
- 230000001717 pathogenic effect Effects 0.000 abstract description 5
- 240000009022 Smilax rotundifolia Species 0.000 abstract description 3
- 235000003205 Smilax rotundifolia Nutrition 0.000 abstract description 3
- 239000013589 supplement Substances 0.000 abstract description 2
- 241000972673 Phellodendron amurense Species 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 17
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 13
- 229940116269 uric acid Drugs 0.000 description 13
- 210000003734 kidney Anatomy 0.000 description 11
- 206010018634 Gouty Arthritis Diseases 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 230000001988 toxicity Effects 0.000 description 8
- 231100000419 toxicity Toxicity 0.000 description 8
- 206010020751 Hypersensitivity Diseases 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 208000026935 allergic disease Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 108010074051 C-Reactive Protein Proteins 0.000 description 5
- 102100032752 C-reactive protein Human genes 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 238000013268 sustained release Methods 0.000 description 5
- 239000012730 sustained-release form Substances 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 230000009610 hypersensitivity Effects 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 238000004062 sedimentation Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000766380 Iphigenia Species 0.000 description 3
- 230000006578 abscission Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960001338 colchicine Drugs 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 239000009765 shen ling bai zhu Substances 0.000 description 2
- 239000009874 shenqi Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 241000427159 Achyranthes Species 0.000 description 1
- 241000271039 Agkistrodon Species 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000244987 Daiswa polyphylla Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241001489978 Eupolyphaga Species 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010021131 Hypouricaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 241000283956 Manis Species 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000131808 Scolopendra Species 0.000 description 1
- 241000522620 Scorpio Species 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 231100000850 chronic interstitial nephritis Toxicity 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000001255 hallux Anatomy 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000008738 huangbai Substances 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 208000016839 purine metabolism disease Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000009490 scorpio Substances 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/583—Snakes; Lizards, e.g. chameleons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/648—Myriapods, e.g. centipedes or millipedes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/732—Chaenomeles, e.g. flowering quince
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8884—Arisaema, e.g. Jack in the pulpit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Insects & Arthropods (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the field of traditional Chinese medicine formulas, in particular to a formula for dredging collaterals and eliminating turbidity and a using method thereof. Aims to solve the problem of narrow application field of the medicament for dredging collaterals and dissolving turbidity in the prior art. The traditional Chinese medicine formula comprises, by weight, 1-25g of rhizoma atractylodis, 1-10g of phellodendron bark, 1-60g of semen coicis, 1-30g of radix cyathulae, 1-25g of edible tulip, 1-60g of rhizoma smilacis glabrae, 1-30g of rhizoma paridis, 1-24g of safflower, 1-24g of earthworm, 1-50g of pawpaw, 1-30g of yam rhizome and ash bark, and has the advantages that: the prescription for removing obstruction in channels and eliminating turbid pathogen clears heat and promotes diuresis, and simultaneously supplements with edible tulip, glabrous greenbrier rhizome, yam rhizome, rhizoma paridis, safflower, pawpaw, ash bark, earthworm and the like to promote diuresis, detoxify, remove obstruction in channels and relieve pain, thereby treating both symptoms and root causes. More and better treatment schemes are provided for the traditional Chinese medicine treatment of gout in the acute stage.
Description
Technical Field
The invention relates to the field of traditional Chinese medicine formulas, in particular to a formula for dredging collaterals and eliminating turbidity and a using method thereof.
Background
Gout is a crystal-related arthropathy caused by deposition of mono-sodiuurate. Acute gouty arthritis is mainly caused by inflammatory reaction caused by sodium urate micro-crystallization, mainly has the symptoms of severe pain, acute morbidity, red swelling and hot pain of joints and surrounding soft tissues and the like, and movement disorder of the joint is generally caused in ankle joints and big toe joints. The kidneys are often involved in the later stages leading to chronic interstitial nephritis and uric acid kidney stones.
Modern medicine considers that gout is a disease caused by purine metabolism disorder caused by genetic or acquired reasons and urate deposited in kidney, joints and the like. When uric acid is produced excessively, the saturation degree of urate in blood exceeds a normal range, the state is called hyperuricemia, and when the condition occurs, urate crystals are easily deposited inside and outside joint tissues, so that acute inflammatory reaction and chronic functional damage are caused, and the condition is called gout.
Modern medicine mostly applies non-steroidal anti-inflammatory drugs, colchicine, glucocorticoid and the like to symptomatic treatment during acute attack of gouty arthritis, and although the medicine has the effects of diminishing inflammation and relieving pain in a short period, the medicine has large side effects and more adverse reactions, such as kidney damage, gastrointestinal tract reaction, bone marrow suppression and the like, and has high recurrence rate. With the further understanding of the gouty arthritis by the traditional Chinese medicine, the traditional Chinese medicine shows unique advantages in the prevention and treatment of the gouty arthritis, and can prevent relapse while removing causes and improving symptoms. Therefore, it is a trend in treatment to develop the advantages of traditional Chinese medicine and find an effective treatment method with few side effects. In the field of traditional Chinese medicine, the traditional Chinese medicine formula is used for dredging collaterals and dissolving turbidity at the present stage, and is used for treating nephropathy, but few in diagnosis and treatment attempts of gout, so that the application aims to provide the traditional Chinese medicine formula for applying the traditional Chinese medicine formula in the field of gout
Disclosure of Invention
The invention aims to solve the problem of narrow application field of the collateral-dredging and turbidity-removing medicament in the prior art.
The specific scheme of the invention is as follows: a prescription for removing obstruction in channels and eliminating turbid pathogen is designed, and a traditional Chinese medicine formula comprises, by weight, 1-25g of rhizoma atractylodis, 1-10g of golden cypress, 1-60g of semen coicis, 1-30g of radix cyathulae, 1-25g of Indian iphigenia bulb, 1-60g of rhizoma smilacis glabrae, 1-30g of rhizoma paridis, 1-24g of safflower, 1-24g of earthworm, 1-50g of pawpaw, 1-30g of rhizoma dioscoreae hypoglaucae and 1-25g of cortex fraxini. .
The traditional Chinese medicine composition comprises, by weight, 15g of rhizoma atractylodis, 12g of golden cypress, 40g of semen coicis, 25g of radix cyathulae, 15g of edible tulip, 45g of rhizoma smilacis glabrae, 15g of rhizoma paridis, 12g of safflower, 12g of earthworm, 30g of pawpaw, 15g of rhizoma dioscoreae hypoglaucae and 20g of cortex fraxini.
Or also comprises the following components of 1 to 25g of arisaema cum bile and 1 to 25g of concretio silicea bambusae in parts by weight.
Also comprises the following components of 1 to 25g of zedoary, 1 to 25g of pseudo-ginseng and 1 to 10g of ground beetle in parts by weight;
also comprises the following components of 1-10g of pangolin, 1-10g of long-noded pit viper, 1-121g of scorpion and 1-6g of centipede in parts by weight.
Also comprises the following components by weight portion, 1-25g of cortex moutan, 1-25g of red peony root, 1-25g of radix rehmanniae and 1-25g of lithospermum.
The administration mode is as follows: the decoction for dredging collaterals and eliminating turbid is taken twice a day in the morning and evening in 1 dose (400 ml in total, packaged in 2 bags); the ibuprofen sustained-release capsule simulating medicine is 1 granule each time and 2 times a day; taken for 1 week.
The invention has the beneficial effects that:
after one treatment cycle, the patient's blood uric acid decreased, urine uric acid increased, and both blood sedimentation and hypersensitivity C-reactive protein decreased substantially to normal. The traditional Chinese medicine has the advantages of excellent effect and small side effect for treating gouty arthritis, and has the effects of clearing heat and promoting diuresis, and simultaneously assisting with Indian iphigenia bulb, glabrous greenbrier rhizome, yam rhizome, paris polyphylla, safflower, pawpaw, ash bark, earthworm and the like, promoting diuresis, detoxifying, dredging collaterals and relieving pain, and treating both principal and secondary aspects of diseases. Provides more and better treatment schemes for the traditional Chinese medicine treatment of gout in the acute stage.
Detailed Description
The following description is presented in conjunction with the preferred embodiments of the present invention, and it is to be understood that the preferred embodiments described herein are presented only for the purpose of illustrating and explaining the present invention, and are not intended to limit the present invention.
Example 1
A formula of a traditional Chinese medicine for dredging collaterals and eliminating turbid pathogen comprises, by weight, 1-25g of rhizoma atractylodis, 1-10g of golden cypress, 1-60g of semen coicis, 1-30g of radix cyathulae, 1-25g of edible tulip, 1-60g of rhizoma smilacis glabrae, 1-30g of rhizoma paridis, 1-24g of safflower, 1-24g of earthworm, 1-50g of pawpaw, 1-30g of rhizoma dioscoreae hypoglaucae and 1-25g of cortex fraxini.
The traditional Chinese medicine composition comprises, by weight, 15g of rhizoma atractylodis, 12g of golden cypress, 40g of semen coicis, 25g of radix cyathulae, 15g of edible tulip, 45g of rhizoma smilacis glabrae, 15g of rhizoma paridis, 12g of safflower carthamus, 12g of earthworm, 30g of pawpaw, 15g of rhizoma dioscoreae hypoglaucae and 20g of cortex fraxini.
After each decoction is formed, 1 particle of the ibuprofen slow release capsule simulant is combined, and the ibuprofen slow release capsule is taken 2 times a day.
The administration and case modes of the reagent are as follows:
according to the research, patients with the dampness-heat internal accumulation syndrome in the acute stage of gout, who meet the diagnosis standard, are selected from 7 months to 10 months from 2021 in 2019, and the clinical curative effect of the collateral-dredging and turbidity-removing formula on treating the dampness-heat internal accumulation type gout in the acute stage is observed by randomly contrasting the test method.
1. Diagnostic criteria gout classification criteria, gout acute phase 2015. The traditional Chinese medicine diagnosis standard refers to the content of 'tenth edition of traditional Chinese medicine diagnostics', and the internal retention of damp-heat: red, swollen and hot pain in joints, fever or no fever, yellow and greasy or thick and greasy tongue coating, and wiry and slippery pulse.
2. Inclusion criteria meet the diagnostic criteria set forth above; the age is between 18 and 65 years.
3. Eliminating allergy of the medicinal ingredients of the standard prescription for dredging collaterals and eliminating turbidity or ibuprofen allergy; alcohol or drug abuse; patients with serious primary diseases such as cardiovascular and cerebrovascular diseases, endocrine, liver, kidney, hematopoietic system, etc.; psychotic patients; pregnant and lactating women.
4. Removing and falling-off standard misdiagnosis and misinclusion; those with severe adverse reactions during the study, including but not limited to cardiovascular events, severe liver, kidney impairment, gastrointestinal bleeding, etc.; other diseases appearing during the study may require treatment to affect efficacy; those without follow-up records; self-administration of other drugs to prevent evaluation of drug effect; the patient loses visit or quits by himself; cases of blindness or emergency uncovering.
The treatment groups and the control groups are randomly divided by a random number generator method according to the numbering of the treatment orders.
Treatment groups: avoid drinking alcohol and low purine diet. Adopts a prescription decoction (uniformly processed and prepared by a prescription of a traditional Chinese medicine of Xiaotong) for removing obstruction in channels and dissolving turbidity and an ibuprofen sustained-release capsule (Fenbide) simulation medicine (red starch capsule). The decoction for dredging collaterals and eliminating turbid is taken twice a day in the morning and evening in 1 dose (400 ml in total, packaged in 2 bags); the ibuprofen sustained-release capsule simulating medicine is 1 granule each time and 2 times a day; taken for 1 week.
The prescription for removing obstruction in channels and eliminating turbid pathogen comprises: 15g of rhizoma atractylodis, 12g of golden cypress, 40g of semen coicis, 25g of radix cyathulae, 15g of Indian iphigenia bulb, 45g of rhizoma smilacis glabrae, 15g of rhizoma paridis, 12g of safflower, 12g of earthworm, 30g of pawpaw, 15g of rhizoma dioscoreae hypoglaucae and 20g of cortex fraxini.
The control group was kept on alcohol and low purine diet. The ibuprofen sustained-release capsule (Fenbide) (Chinese medicine standard H10900089 of Zhongmei Tianjin Shike pharmaceutical Co., Ltd.) is adopted for treatment, and caramel water is given as a placebo, and the usage is the same as the traditional Chinese medicine decoction. The ibuprofen sustained-release capsule is 1 granule each time and 2 times a day; taken for 1 week.
A patient management discipline. Daily telephone follow-up, abstinence from alcohol and low-purine diet guidelines, daily pain relief was registered (self-scoring by VAS score). The patients who can not take the medicine according to the requirements or have serious adverse reactions are subjected to the re-diagnosis and the elimination.
1, before and after 24 hours of treatment, VAS score after one week, blood uric acid, blood sedimentation and hypersensitivity C-reactive protein.
2 safety items, blood routine, abnormal change of liver and kidney function, gastrointestinal hemorrhage and severity and adverse event record of each group before and after treatment.
Statistical processing of data with SPSS19.0 statistical software
Then collecting two groups of data, and using the obtained metering dataPerforming statistical treatmentThe homogeneity of variance is determined by F test, and is given to corresponding t test, p<Significance was considered at 5%. Gender was checked using Caller's count data.
76 cases were included in the group, between 7 months in 2019 and 10 months in 2021. 16 cases of abscission, 12 cases of abscission are managed and controlled by epidemic situation and are not subjected to repeated diagnosis and follow-up, and 4 cases of abscission are caused by individual reasons and are not finished with the experiment. The total collection is completed by 60 cases. The specific cases are as follows:
Table 1: counting data of sex use, checking by chi-square
According to clinical observation, the liver and kidney function and blood coagulation and hematopoiesis function of 60 patients have no abnormality.
1. Case general situation comparison: as can be seen from Table 1, the age, sex and time of onset of disease of the patients in the two groups were statistically analyzed, and the differences between the two groups were not significant.
2. Consistency comparison before admission: according to tables 4-6, the results show that there is no significant difference in VAS score, blood uric acid, blood sedimentation, and hypersensitivity C-reactive protein, and the results are comparable.
3. Change after treatment: the VAS score was improved after 24 hours after treatment, and after one week, the VAS score was improved significantly, and the improvement in the treated group was better than that in the control group. After 7 days of treatment, the blood uric acid of the treatment group is reduced and the urine uric acid is increased compared with the control group, and the blood sedimentation and the hypersensitivity C-reactive protein of the two groups are basically reduced to be normal without statistical difference.
Through the above examples, it can be confirmed that the formula for dredging collaterals and eliminating turbidity can obviously improve pain symptoms of patients in the acute stage of gout with syndrome of damp-heat accumulation, wherein the symptom relieving degree after 24 hours is slightly worse than that of ibuprofen. And the gout improving condition after 7 days is better than that of ibuprofen. The inflammation index is reduced to normal after treatment. The treatment of the hypouricemia and the increase of the uric acid in urine in the group suggests that the recipe may increase the excretion of uric acid, thereby improving the symptoms and simultaneously playing the role of reducing uric acid.
The prescription for removing obstruction in channels and eliminating turbid pathogen clears heat and promotes diuresis, and simultaneously supplements with edible tulip, glabrous greenbrier rhizome, yam rhizome, rhizoma paridis, safflower, pawpaw, ash bark, earthworm and the like to promote diuresis, detoxify, remove obstruction in channels and relieve pain, thereby treating both symptoms and root causes. Provides more and better treatment schemes for the traditional Chinese medicine treatment of gout in the acute stage.
The theoretical basis of the invention is as follows:
the gout is divided into an acute attack stage, an intermittent stage and a chronic arthritis stage, wherein in the acute attack stage, the formula uses the Simiao powder and the five flavors of disinfectant drinks, and is supplemented with spleen-strengthening and stomach-harmonizing medicines; in the intermission period, the three-kernel decoction and the yang-invigorating and stomach-benefiting decoction are used together with the blood-activating and collateral-dredging medicines; in the chronic arthritis stage, Shenling Baizhu san and Shenqi pills are used, and in the acute stage, the Shenling Baizhu san and Shenqi pills are used for clearing heat and removing toxicity, and dredging collaterals and promoting diuresis; in the chronic and intermittent periods, it is usually used to invigorate the spleen and warm the kidney, resolve blood stasis and remove dampness. The acute attack stage is mainly characterized by turbid toxin and fatigue, and the swelling and pain are relieved when the turbid toxin is cleared away; in the chronic stage and the intermittent stage, the spleen and kidney should be properly adjusted and benefited on the basis of discharging and resolving turbidity-toxin, and the treatment of both principal and secondary aspects should be performed.
According to the classification standard established by the State administration of traditional Chinese medicine, gout is divided into 4 types, namely damp-heat accumulation type, stagnant heat retardation type, phlegm retardation type and liver-kidney yin deficiency type; wherein, the damp-heat accumulation type is treated by the method of clearing heat and removing dampness, and activating blood and removing toxicity and dissipating stagnation, and the formula is modified by Simiao powder; for blood stasis and heat stagnation type, it is used to clear heat and remove toxicity, unblock collaterals and alleviate pain, and Zhi Tan Teng Tang is used in the recipe; for phlegm-turbidity type, Luo Mi Tang is used to treat the syndrome of marked diseases and transforming into turbid; for liver and kidney yin deficiency type, it is indicated for tonifying liver and kidney, and is indicated for Liu Wei Di Huang Wan.
According to the traditional Chinese medicine composition, rhizoma atractylodis has the effects of eliminating dampness and strengthening spleen, expelling wind and removing cold, improving eyesight, cortex phellodendri has the effects of clearing heat and eliminating dampness, purging fire and relieving toxicity, edible tulip has the effects of clearing heat and removing toxicity, resolving carbuncle and resolving masses, rhizoma smilacis glabrae has the effects of removing toxicity, dehumidifying and easing joint movement, rhizoma paridis has the effects of clearing heat and removing toxicity, relieving swelling and pain, cooling liver and arresting convulsion, safflower has the effects of promoting blood circulation and removing blood stasis, dissipating dampness and removing swelling, earthworm has the effects of clearing heat and arresting convulsion, dredging collaterals, relieving asthma and inducing diuresis, and pawpaw has the effects of relaxing tendons and activating collaterals, harmonizing stomach and eliminating dampness.
Modern medicine mostly applies non-steroidal anti-inflammatory drugs, colchicine, glucocorticoid and the like to symptomatic treatment during acute attack of gouty arthritis, and although the medicine has the effects of diminishing inflammation and relieving pain in a short period, the medicine has large side effects and more adverse reactions, such as kidney damage, gastrointestinal tract reaction, bone marrow suppression and the like, and has high recurrence rate. With the further understanding of the gouty arthritis by the traditional Chinese medicine, the traditional Chinese medicine shows unique advantages in the prevention and treatment of the gouty arthritis, and can prevent relapse while removing causes and improving symptoms. Therefore, it is a trend in treatment to develop the advantages of traditional Chinese medicine and find an effective treatment method with few side effects.
This disease is caused by damp-heat injected into the lower energizer, and is indicated for clearing heat, drying dampness and alleviating pain. In the prescription, Huangbai is a monarch drug which can clear damp-heat in lower energizer and cang Zhu can dry dampness and strengthen spleen to promote transportation; achyranthes root, radix Achyranthis bidentatae tonifies liver and kidney, strengthens tendons and bones, and draws guiding herbs downward. Therefore, for the treatment of numbness of both feet due to damp-heat in the lower energizer, the combination of Yi ren for excreting dampness, strengthening spleen, relaxing tendons and relieving spasm is combined with Fu Ling, gan floor, Di Long for clearing heat and removing toxicity. Dampness eliminating, joint smoothing, safflower blood circulation promoting and pain relieving in the formula, pawpaw channels smoothing and collaterals activating, yam rhizome and ash bark in the formula have the functions of clearing heat and drying dampness, and promoting diuresis and removing obstruction in channels, and are used as adjuvant drugs.
In addition and subtraction processing, addition and subtraction: rhizoma arisaematis cum bile and concretio silicea Bambusae seu Schizostachyi may be added for patients with subcutaneous nodule due to turbid phlegm retention; obvious blood stasis, arthralgia, swelling and deformity and difficult movement. Rhizoma Curcumae, radix Notoginseng, and Eupolyphaga Seu Steleophaga can be added to make tongue purple and dark and pulse astringent; for those with phlegm and blood stasis and pain, squama Manis, Agkistrodon, Scorpio, and Scolopendra can be added to remove meridian obstruction. Cortex moutan, radix Paeoniae Rubra, radix rehmanniae, and radix Arnebiae may be added to treat skin erythema and erythra, and has effects in clearing away heat, cooling blood, promoting blood circulation, and removing blood stasis.
Finally, it should be noted that: although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that changes may be made in the embodiments and/or equivalents thereof without departing from the spirit and scope of the invention. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (7)
1. A formula for dredging collaterals and eliminating turbidity for treating gout is characterized in that: the traditional Chinese medicine formula comprises, by weight, 1-25g of rhizoma atractylodis, 1-10g of golden cypress, 1-60g of semen coicis, 1-30g of radix cyathulae, 1-25g of edible tulip, 1-60g of rhizoma smilacis glabrae, 1-30g of rhizoma paridis, 1-24g of safflower, 1-24g of earthworm, 1-50g of pawpaw, 1-30g of yam rhizome and ash bark.
2. The collateral-dredging turbidity-eliminating formulation according to claim 1, wherein: the traditional Chinese medicine composition comprises, by weight, 15g of rhizoma atractylodis, 12g of golden cypress, 40g of semen coicis, 25g of radix cyathulae, 15g of edible tulip, 45g of rhizoma smilacis glabrae, 15g of rhizoma paridis, 12g of safflower, 12g of earthworm, 30g of pawpaw, 15g of yam rhizome and 20g of cortex fraxini.
3. The collateral-dredging turbidity-eliminating formulation according to claim 1, wherein: also comprises the following components of 1 to 25g of arisaema cum bile and 1 to 25g of concretio silicea bambusae in parts by weight.
4. The collateral-dredging turbidity-eliminating formulation according to claim 1, wherein: also comprises the following components of 1-25g of zedoary, 1-25g of pseudo-ginseng and 1-10g of ground beetle in parts by weight.
5. The collateral-dredging turbidity-eliminating formulation according to claim 1, wherein: also comprises the following components of 1-10g of pangolin, 1-10g of long-noded pit viper, 1-121g of scorpion and 1-6g of centipede in parts by weight.
6. The collateral-dredging turbidity-eliminating formulation according to claim 1, wherein: also comprises the following components by weight portion, 1-25g of cortex moutan, 1-25g of red peony root, 1-25g of dried rehmannia root and 1-25g of lithospermum.
7. The use method of the collateral-dredging and turbidity-eliminating prescription according to claim 1, characterized in that: after each decoction is formed, 1 particle of the ibuprofen slow release capsule simulant is taken 2 times a day.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210297441.7A CN114632128A (en) | 2022-03-24 | 2022-03-24 | Collateral-dredging and turbid-removing formula and using method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210297441.7A CN114632128A (en) | 2022-03-24 | 2022-03-24 | Collateral-dredging and turbid-removing formula and using method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114632128A true CN114632128A (en) | 2022-06-17 |
Family
ID=81949807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210297441.7A Pending CN114632128A (en) | 2022-03-24 | 2022-03-24 | Collateral-dredging and turbid-removing formula and using method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114632128A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116270922A (en) * | 2022-12-27 | 2023-06-23 | 福建中医药大学 | Prescription for eliminating turbid pathogen, resolving masses and removing arthralgia and application thereof |
-
2022
- 2022-03-24 CN CN202210297441.7A patent/CN114632128A/en active Pending
Non-Patent Citations (2)
Title |
---|
蒋巧燕等: "中药内服外用治疗急性痛风性关节炎疗效观察", 《光明中医》 * |
郑其凤等: "中西医结合治疗痛风性关节炎35例", 《中国民族民间医药》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116270922A (en) * | 2022-12-27 | 2023-06-23 | 福建中医药大学 | Prescription for eliminating turbid pathogen, resolving masses and removing arthralgia and application thereof |
CN116270922B (en) * | 2022-12-27 | 2024-04-19 | 福建中医药大学 | Prescription for eliminating turbid pathogen, resolving masses and removing arthralgia and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101229300B (en) | Chinese traditional medicine preparation for treating bone fracture | |
CN110478452B (en) | Traditional Chinese medicine composition for treating gout and preparation method thereof | |
CN101406688B (en) | Compound formulation for treating rheumatic arthritis and rheumatoid arthritis | |
CN114632128A (en) | Collateral-dredging and turbid-removing formula and using method thereof | |
CN112972635A (en) | A Chinese medicinal composition for treating chronic kidney diseases and chronic renal failure | |
EP1484065A1 (en) | Chinese preparation for treating enteritis ulcer colitis and preparation method thereof | |
CN113209182B (en) | A Chinese medicinal composition for treating rheumatoid arthritis, and its preparation method | |
CN112755140B (en) | Pharmaceutical composition for treating gouty arthritis and preparation method and application thereof | |
CN100579544C (en) | Chinese medicament preparation for treating cholecystitis and gall-stone as well as preparation method thereof | |
CN108619427B (en) | Pain-relieving and acid-reducing herb tea for preventing and treating gouty arthritis | |
CN110478416B (en) | Composition for treating rheumatic and rheumatoid arthritis and preparation method and application thereof | |
CN100534500C (en) | Chinese medicine with wind-dispelling damp-eliminating, collaterals-dredging, coldness-expelling pain-relieving functions and preparation process thereof | |
CN103550744B (en) | A kind of pure Chinese medicinal preparation for oral ulcer | |
CN101590208B (en) | Medicament composition for treating rheumatoid arthritis, and preparation method thereof | |
CN106974958B (en) | Recipe of 'RongjinNiantong' and its prepn and use | |
CN108743885A (en) | A kind of Chinese medicine and preparation method thereof for treating Diabetic Macrovascular Complications | |
CN106668787A (en) | Traditional Chinese medicine honeyed pill for treating hepatonecrosis and liver cancer and preparation method of traditional Chinese medicine honeyed pill | |
CN114848703B (en) | Tibetan medicine formula with rheumatoid arthritis treatment effect, preparation method and application thereof | |
CN103349767B (en) | Inula nervosa Wall oil capsule preparation and preparation method thereof | |
CN114984160B (en) | Mongolian medicine for treating alcoholic liver disease | |
CN110548118B (en) | Traditional Chinese medicine compound for preventing and treating primary biliary cholangitis and preparation method and application thereof | |
CN106266152A (en) | A kind of pharmaceutical composition treating eczema and its production and use | |
CN106729213B (en) | Compound traditional Chinese medicine for treating rheumatoid arthritis in acute stage and application thereof | |
CN101167915B (en) | Traditional Chinese medicine for treating chronic superficial gastritis and its preparation method | |
CN104644950A (en) | Ointment for treating rheumatoid arthritis and preparation method of ointment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220617 |
|
RJ01 | Rejection of invention patent application after publication |